Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study

Alessandra Mangia

Open source

DOI
10.20524/aog.2017.0136
Published
2017
Container
Annals of Gastroenterology
Publisher
Hellenic Society of Gastroenterology
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.20524/aog.2017.0136,
  title = {Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study},
  author = {Alessandra Mangia},
  year = {2017},
  journal = {Annals of Gastroenterology},
  doi = {10.20524/aog.2017.0136},
  url = {https://doi.org/10.20524/aog.2017.0136}
}

RIS

TY  - JOUR
TI  - Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study
AU  - Alessandra Mangia
PY  - 2017
JO  - Annals of Gastroenterology
DO  - 10.20524/aog.2017.0136
UR  - https://doi.org/10.20524/aog.2017.0136
ER  - 

APA

Mangia, A. (2017). Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. Annals of Gastroenterology. https://doi.org/10.20524/aog.2017.0136

Source records